NASDAQ
Intra-Cellular Therapies, Inc. (ITCI) has a free cash flow growth of 53.52% as of Friday, May 29, 2026. This represents a 103.05% increase compared to its 12-month average of -1756.95%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.